If you have been reading about Toll-like receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Early work on thymic extracts in the 1960s described a heat-stable acidic fraction containing many polypeptides. Separation of that mixture yielded individual components, and thymosin alpha-1 was named as one of them on the basis of assays for T-cell activity. The first preparations came from calf thymus, while subsequent research and clinical material has been chemically synthesized. Nomenclature in older papers is inconsistent, and the same peptide sometimes appears under different designations, which complicates literature searches.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Clinical interest has centered on chronic viral hepatitis, on immune restoration in various conditions, and on use as an adjuvant intended to improve responses to vaccines. Trials have reported mixed results, and regulatory status differs sharply between countries; in some places it is a prescription product, while elsewhere it is sold without an approved therapeutic indication. Because published studies vary widely in design, population, and endpoints, comparisons across them are difficult and no single conclusion covers the whole literature.
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
It’s a fight for our national security." He advocated for a special inspector general to monitor the aid given to Ukraine following Russia's invasion. Kennedy expressed concern that money was being misspent, saying, "Ukraine is not without flaws. We've heard several unsettling reports of bad actors exploiting our generosity… We trust that our friends in Ukraine take corruption seriously. We must verify, too."
A tactic in which security forces pose as 'pseudo' insurgents to gather intelligence was developed prior to the Rhodesian Bush War, and had also been used by police forces. Pseudo operations involve security force personnel being trained to closely imitate insurgents. Teams of these personnel then enter regions where insurgents are active and portray themselves as insurgents. After establishing credibility, the team collects intelligence on actual insurgents and their sources of support. These tactics can be most necessary in regions where the insurgents have eliminated the government's sources of intelligence, as was the case in north-eastern Rhodesia in 1973. In general, 'pseudo' teams undertake only intelligence collection work, and do not attack insurgents themselves. 'Pseudo' tactics are generally most effective when the teams include former insurgents who have been 'turned' to side with the government. The effectiveness of these tactics is partially dependent on their use not becoming known, as this will lead to insurgents improving their security processes. Internationally, there has also been a risk of pseudo units breaking the law. If local civilians learn that the security forces are posing as insurgents and using this as cover to break the law, the tactics can be counter-productive as they will erode support for the government. The British authorities used pseudo tactics during the Malayan Emergency, with this coming to the attention of the Rhodesians who took part in that conflict.
2 Mg(s) + CO2(g) → 2 MgO(s) + C(s) Hence, carbon dioxide fuels rather than extinguishes magnesium fires. Burning magnesium can be quenched by using a Class D dry chemical fire extinguisher, or by covering the fire with sand or magnesium foundry flux to remove its air source.
Sources: en.wikipedia.org
== See also == Amnesic shellfish poisoning Diarrheal shellfish poisoning Neurotoxic shellfish poisoning Harmful algal blooms (see "toxins") Ciguatera Fugu Cyanotoxin Dinoflagellate ecology and physiology (see "neurotoxins", "red tide", and "phosphate") Red tide crisis in Chiloé
=== Individual disorders === N-Acetylglutamate synthase (NAGS) deficiency Carbamoyl phosphate synthetase (CPS) deficiency Ornithine transcarbamoylase (OTC) deficiency Citrullinemia type I (Deficiency of argininosuccinic acid synthase) Argininosuccinic aciduria (Deficiency of argininosuccinic acid lyase) Argininemia (Deficiency of arginase) Ornithine translocase (SLC25A15) deficiency All urea cycle defects, except OTC deficiency, are inherited in an autosomal recessive manner. OTC deficiency is inherited as an X-linked recessive disorder, although some females can show symptoms. Most urea cycle disorders are associated with hyperammonemia, however argininemia and some forms of argininosuccinic aciduria do not present with elevated ammonia.
==== 100–199 ==== Air Fares (Amendment) Regulations 1993 (S.I. 1993/100) Licensing of Air Carriers (Amendment) Regulations 1993 (S.I. 1993/101) Local Government and Housing Act 1989 (Commencement No. 15) Order 1993 (S.I. 1993/105) Education (School Financial Statements) (Prescribed Particulars etc.) Regulations 1993 (S.I. 1993/113) Teachers' Superannuation (Amendment) Regulations 1993 (S.I. 1993/114) British Railways (Penalty Fares) Act 1989 (Activating No. 8) Order 1993 (S.I. 1993/115) A31 Trunk Road (Ashley Heath Grade Separated Junction) Order 1993 (S.I. 1993/116) Local Government Act 1988 (Defined Activities) (Exemption) (Boothferry Borough Council) Order 1993 (S.I. 1993/117) Act of Sederunt (Fees of Messengers-at-Arms) 1993 (S.I. 1993/118) Value Added Tax (General) (Amendment) Regulations 1993 (S.I. 1993/119) Act of Sederunt (Fees of Sheriff Officers) 1993 (S.I. 1993/120) Testing in Primary Schools (Scotland) Revocation Regulations 1993 (S.I. 1993/121) East Birmingham Hospital National Health Service Trust (Change of Name) Order 1993 (S.I. 1993/122) Teddington Memorial Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/123) Revenue Support Grant (Specified Bodies) (Amendment) Regulations 1993 (S.I. 1993/139) A35 Trunk Road (40 mph Speed Limit) Order 2003 (S.I. 1993/142) Food Protection (Emergency Prohibitions) (Oil and Chemical Pollution of Fish) (No.2) Order 1993 (S.I. 1993/143) Council Tax (Additional Provisions for Discount Disregards) (Amendment) Regulations 1993 (S.I. 1993/149) Council Tax (Exempt Dwellings) (Amendment) Order 1993 (S.I.
Sources: en.wikipedia.org
== Viral resistance to interferons == Many viruses have evolved mechanisms to resist interferon activity. They circumvent the IFN response by blocking downstream signaling events that occur after the cytokine binds to its receptor, by preventing further IFN production, and by inhibiting the functions of proteins that are induced by IFN. Viruses that inhibit IFN signaling include Japanese Encephalitis Virus (JEV), dengue type 2 virus (DEN-2), and viruses of the herpesvirus family, such as human cytomegalovirus (HCMV) and Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8). Viral proteins proven to affect IFN signaling include EBV nuclear antigen 1 (EBNA1) and EBV nuclear antigen 2 (EBNA-2) from Epstein-Barr virus, the large T antigen of Polyomavirus, the E7 protein of Human papillomavirus (HPV), and the B18R protein of vaccinia virus. Reducing IFN-α activity may prevent signaling via STAT1, STAT2, or IRF9 (as with JEV infection) or through the JAK-STAT pathway (as with DEN-2 infection). Several poxviruses encode soluble IFN receptor homologs—like the B18R protein of the vaccinia virus—that bind to and prevent IFN interacting with its cellular receptor, impeding communication between this cytokine and its target cells. Some viruses can encode proteins that bind to double-stranded RNA (dsRNA) to prevent the activity of RNA-dependent protein kinases; this is the mechanism reovirus adopts using its sigma 3 (σ3) protein, and vaccinia virus employs using the gene product of its E3L gene, p25.
In the absence of caffeine and when a person is awake and alert, little adenosine is present in CNS neurons. With a continued wakeful state, over time adenosine accumulates in the neuronal synapse, in turn binding to and activating adenosine receptors found on certain CNS neurons; when activated, these receptors produce a cellular response that ultimately increases drowsiness. When caffeine is consumed, it antagonizes adenosine receptors; in other words, caffeine prevents adenosine from activating the receptor by blocking the location on the receptor where adenosine binds to it. As a result, caffeine temporarily prevents or relieves drowsiness, and thus maintains or restores alertness.
== See also == Chalcedony – Microcrystalline or cryptocrystalline form of silica Chert – Hard, fine-grained sedimentary rock composed of cryptocrystalline silica Flint – Cryptocrystalline form of the mineral quartz Concretion – In geology, a type of compact mass Fossil – Preserved remains or traces of organisms from a past geological age Petrogenesis – Processes that form rock
24195Am + 42He → 24397Bk + 2 10n After the irradiation, the coating was dissolved with nitric acid and then precipitated as the hydroxide using concentrated aqueous ammonia solution. The product was centrifugated and re-dissolved in nitric acid. To separate berkelium from the unreacted americium, this solution was added to a mixture of aqueous ammonia and ammonium sulfate and heated in the presence of atmospheric oxygen to convert all the dissolved americium into the oxidation state +6. Unoxidized residual americium was precipitated by the addition of hydrofluoric acid as americium(III) fluoride (AmF3). This step yielded a mixture of the accompanying product curium and the expected element 97 in form of trifluorides. The mixture was converted to the corresponding hydroxides by treating it with potassium hydroxide, and after centrifugation, was dissolved in perchloric acid.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.